Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference
27 2월 2023 - 10:00PM
Business Wire
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing
and commercializing software-based medicines called prescription
digital therapeutics (PDTs), today announced the Company will
participate in the 43rd Annual Cowen Healthcare Conference being
held March 6-8, 2023 in Boston. Corey McCann, M.D., Ph.D.,
President and CEO, will represent the Company in an analyst-led
fireside chat on Monday, March 6 at 9:10 a.m. Eastern Time.
A live audio webcast can be accessed by clicking here and will
be made available in the Investors section of Pear’s website at
www.peartherapeutics.com. A replay of the webcast will be available
on Pear’s website for up to 30 days following the live
presentation.
About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is
the parent company of Pear Therapeutics (US), Inc. Pear is the
leader in developing and commercializing software-based medicines,
called prescription digital therapeutics (PDTs). Pear aims to
redefine care through the widespread use of clinically validated
software-based therapeutics to provide better outcomes for
patients, smarter engagement and tracking tools for clinicians, and
cost-effective solutions for payers. Pear has the first end-to-end
platform to discover, develop, and deliver PDTs to patients and a
pipeline of products and product candidates across therapeutic
areas, including the first three PDTs with disease treatment claims
from the FDA. Pear’s product, reSET®, for the treatment of
substance use disorder, was the first PDT to receive marketing
authorization from the FDA to treat disease. Pear’s second product,
reSET-O®, for the treatment of opioid use disorder, was the first
PDT to receive Breakthrough Designation. Pear’s third product,
Somryst® for the treatment of chronic insomnia, was the first PDT
submitted through FDA’s traditional 510(k) pathway while
simultaneously reviewed through FDA’s Software Precertification
Pilot Program. For more information, visit Pear at
www.peartherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230227005114/en/
Media and Investors: Meara Murphy Senior Director,
Corporate Communications meara.murphy@peartherapeutics.com
Pear Therapeutics (NASDAQ:PEAR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Pear Therapeutics (NASDAQ:PEAR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Pear Therapeutics Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Pear Therapeutics Inc News Articles